X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
CT7001 (samuraciclib) is an investigational oral and first-in-class inhibitor of CDK7, in combination with ARV-471 (vepdegestrant), an investigational oral PROTAC degrader is being evaluated for the treatment of ER+, HER2- metastatic breast cancer.
Lead Product(s): Samuraciclib,Vepdegestrant
Therapeutic Area: Oncology Product Name: CT7001
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2024
Details:
ARV-471 (vepdegestrant) is an investigational, orally bioavailable PROTAC protein degrader designed to specifically target and degrade the estrogen receptor. It is being evaluated in phase 3 clinical trials for the treatment of patients with ER+/HER2- breast cancer.
Lead Product(s): Vepdegestrant
Therapeutic Area: Oncology Product Name: ARV-471
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 06, 2024
Details:
Arvinas expects to use net proceeds to advance its clinical development programs and preclinical pipeline, including ARV-471 (vepdegestrant), an investigational orally bioavailable PROTAC® protein degrader.
Lead Product(s): Vepdegestrant
Therapeutic Area: Oncology Product Name: ARV-471
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: BofA Securities
Deal Size: $350.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement November 27, 2023
Details:
ARV-471 (vepdegestrant) is an investigational, orally bioavailable PROTAC® protein degrader designed to specifically target and degrade the estrogen receptor for the treatment of patients with early and locally advanced breast cancer.
Lead Product(s): Vepdegestrant
Therapeutic Area: Oncology Product Name: ARV-471
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 31, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
